# Macular hole formation following intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report

**Authors:** Daisuke Muramatsu, Ryosuke Mitsuhashi, Takuya Iwasaki, Hiroshi Goto, Masahiro Miura

PMC · DOI: 10.1186/s13104-015-1324-4 · 2015-08-19

## TL;DR

A rare case report shows a macular hole developing after ranibizumab treatment for retinal vein occlusion, which was later successfully treated with surgery.

## Contribution

Reports a rare complication of macular hole formation following ranibizumab injection for branch retinal vein occlusion.

## Key findings

- A full thickness macular hole developed nine days after ranibizumab injection in a patient with branch retinal vein occlusion.
- The macular hole was successfully closed after vitrectomy and cataract surgery, improving visual acuity to 20/40.

## Abstract

Macular hole formation after anti-vascular endothelial growth factor therapy is a rare complication. We report macular hole formation after intravitreal ranibizumab injection for branch retinal vein occlusion.

A 63-year-old Asian male was treated with intravitreal ranibizumab injection for chronic macular edema with branch retinal vein occlusion in his right eye. Before treatment, best-corrected visual acuity in his right eye was 20/200. Nine days after injection, a full thickness macular hole developed with reduction of macular edema. After pars plana vitrectomy combined with cataract surgery, the macular hole was successfully closed, and the best-corrected visual acuity in his right eye improved to 20/40.

The possibility of an infrequent complication like macular hole should be considered for intravitreal ranibizumab for macular edema with branch retinal vein occlusion.

## Linked entities

- **Diseases:** macular hole (MONDO:0006843)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** visual impairment (MESH:D014786), retinal hemorrhage (MESH:D012166), MH (MESH:D012167), CNV (MESH:D020256), intraretinal edema (MESH:D004487), fibrosis (MESH:D005355), retinal detachment (MESH:D012163), diabetes mellitus (MESH:D003920), vitreous macular traction (MESH:D014823), AMD (MESH:D008268), PVD (MESH:D020255), Macular edema (MESH:D008269), cataract (MESH:D002386), retinal vascular disease (MESH:D012164), polypoidal choroidal vasculopathy (MESH:D000092342), BRVO (MESH:D012170), hyperlipidemia (MESH:D006949), proliferative diabetic retinopathy (OMIM:603933), hypertension (MESH:D006973)
- **Chemicals:** ranibizumab (MESH:D000069579), sulfur hexafluoride (MESH:D013459), Avastin (MESH:D000068258), Fluorescein (MESH:D019793), steroid (MESH:D013256),  (MESH:D042461),  (MESH:D020533)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** RPE — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_IQ82)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC4541740/full.md

---
Source: https://tomesphere.com/paper/PMC4541740